Analysts at Craig Hallum assumed coverage on shares of Cardiff Oncology (NASDAQ:CRDF – Get Free Report) in a research report issued to clients and investors on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Craig Hallum’s price objective suggests a potential upside of 261.99% from the company’s current price.
Cardiff Oncology Stock Performance
Shares of CRDF opened at $2.21 on Friday. The business’s 50-day moving average is $2.30 and its two-hundred day moving average is $3.27. The company has a market capitalization of $102.88 million, a P/E ratio of -2.46 and a beta of 1.95. Cardiff Oncology has a fifty-two week low of $0.94 and a fifty-two week high of $6.42.
Cardiff Oncology (NASDAQ:CRDF – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.12 million. During the same period last year, the business earned ($0.25) earnings per share. Analysts forecast that Cardiff Oncology will post -1 EPS for the current year.
Institutional Trading of Cardiff Oncology
Cardiff Oncology Company Profile
Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
Read More
- Five stocks we like better than Cardiff Oncology
- Using the MarketBeat Dividend Tax Calculator
- Casey’s General Stores: The Dividend Growth Stock You Can’t Miss
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- The Fundamental Issue With NVIDIA Might Be Its Fundamentals
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Stocks to Watch as Firms Cut Costs Ahead of Potential Recession
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.